178 related articles for article (PubMed ID: 34358529)
1. Epigenetic Regulation of Apoptosis in Cutaneous T-Cell Lymphoma: Implications for Therapy with Methotrexate, Jak Inhibitors, and Resveratrol.
Nihal M; Wu J; Stonesifer CJ; Daniels J; Choi J; Geskin L; Rook AH; Wood GS
J Invest Dermatol; 2022 Feb; 142(2):493-496.e7. PubMed ID: 34358529
[No Abstract] [Full Text] [Related]
2. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
Kato Y; Egusa C; Maeda T; Tsuboi R
J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218
[TBL] [Abstract][Full Text] [Related]
3. Epigenetically Enhanced PDT Induces Significantly Higher Levels of Multiple Extrinsic Pathway Apoptotic Factors than Standard PDT, Resulting in Greater Extrinsic and Overall Apoptosis of Cutaneous T-cell Lymphoma.
Salva KA; Kim YH; Rahbar Z; Wood GS
Photochem Photobiol; 2018 Sep; 94(5):1058-1065. PubMed ID: 29675945
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate and Pralatrexate.
Wood GS; Wu J
Dermatol Clin; 2015 Oct; 33(4):747-55. PubMed ID: 26433846
[TBL] [Abstract][Full Text] [Related]
5. Proteasome Inhibitors Interact Synergistically with BCL2, Histone Deacetylase, BET, and Jak Inhibitors against Cutaneous T-Cell Lymphoma Cells.
Xu S; Ren J; Lewis JM; Carlson KR; Girardi M
J Invest Dermatol; 2023 Jul; 143(7):1322-1325.e3. PubMed ID: 36642402
[No Abstract] [Full Text] [Related]
6. miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma.
Manfè V; Biskup E; Rosbjerg A; Kamstrup M; Skov AG; Lerche CM; Lauenborg BT; Odum N; Gniadecki R
PLoS One; 2012; 7(1):e29541. PubMed ID: 22235305
[TBL] [Abstract][Full Text] [Related]
7. Jak-STAT Inhibition Mediates Romidepsin and Mechlorethamine Synergism in Cutaneous T-Cell Lymphoma.
Cortes JR; Patrone CC; Quinn SA; Gu Y; Sanchez-Martin M; Mackey A; Cooke AJ; Shih BB; Laurent AP; Trager MH; Ferrando AA; Geskin LJ; Palomero T
J Invest Dermatol; 2021 Dec; 141(12):2908-2920.e7. PubMed ID: 34089720
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous T-cell lymphoma: Biologic targets for therapy.
Choi J; Foss F
Curr Hematol Malig Rep; 2007 Oct; 2(4):272-7. PubMed ID: 20425380
[TBL] [Abstract][Full Text] [Related]
9. Epigenetics of Cutaneous T-Cell Lymphomas.
Hara N; Sawada Y
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408897
[TBL] [Abstract][Full Text] [Related]
10. [Cutaneous cytotoxic T-cell lymphoma].
Weinstabl A; Megahed M; Rütten A; Rübben A
Hautarzt; 2011 May; 62(5):329-32. PubMed ID: 21445701
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous panniculitic T-cell lymphoma in childhood: successful response to chemotherapy.
Thomson AB; McKenzie KJ; Jackson R; Wallace WH
Med Pediatr Oncol; 2001 Dec; 37(6):549-52. PubMed ID: 11745897
[No Abstract] [Full Text] [Related]
12. A case of primary cutaneous CD4+ small- to medium-sized pleomorphic T-cell lymphoma.
Hou S; Liu X; Liu J; Zhang Z; Wang B; Han C
Eur J Dermatol; 2016 Dec; 26(6):629-630. PubMed ID: 27629423
[No Abstract] [Full Text] [Related]
13. Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma.
Wu J; Wood GS
Arch Dermatol; 2011 Apr; 147(4):443-9. PubMed ID: 21173302
[TBL] [Abstract][Full Text] [Related]
14. Nasal-type NK/T-cell lymphoma successfully treated with ProMACE-CytaBOM therapy.
Isogai R; Kawada A; Hashimoto K; Aragane Y; Tezuka T; Maeda Y; Kanamaru A
Dermatology; 2004; 209(3):243-5. PubMed ID: 15459544
[No Abstract] [Full Text] [Related]
15. TPD7 inhibits the growth of cutaneous T cell lymphoma H9 cell through regulating IL-2R signalling pathway.
Zhu M; Yang L; Shi X; Gong Z; Yu R; Zhang D; Zhang Y; Ma W
J Cell Mol Med; 2020 Jan; 24(1):984-995. PubMed ID: 31742861
[TBL] [Abstract][Full Text] [Related]
16. Treatment of cutaneous T-cell lymphoma by retinoids and calcitriol.
Bagot M
Lancet; 1995 Aug; 346(8971):376-7. PubMed ID: 7623547
[No Abstract] [Full Text] [Related]
17. Transformed cutaneous T cell lymphoma and biclonal gammopathy.
Miralles ES; Núñez M; Boixeda P; Moreno R; Bellas C; Ledo A
Int J Dermatol; 1996 Mar; 35(3):196-8. PubMed ID: 8655237
[No Abstract] [Full Text] [Related]
18. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
[TBL] [Abstract][Full Text] [Related]
19. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
[TBL] [Abstract][Full Text] [Related]
20. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
